Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

References

• HammerSMSaagMSSchechterMTreatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelJAMA2006296782784316905788
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338138538609516219
   PubMed Web of Science ®Google Scholar
• TozziVZaccarelliMBonfigliSDrug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors, and virological outcomeAntivir Ther200611555356016964822
   PubMed Web of Science ®Google Scholar
• CostagliolaDDescampsDAssoumouLPrevalence of HIV-1 drug resistance in treated patients: a French nationwide studyJ Acquir Immune Defic Syndr2007461121817514016
   PubMed Web of Science ®Google Scholar
• HazudaDJFelockPWitmerMInhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cellsScience2000287545364665010649997
   PubMed Web of Science ®Google Scholar
• EspesethASFelockPWolfeAHIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integraseProc Natl Acad Sci U S A20009721112441124911016953
   PubMed Web of Science ®Google Scholar
• CraigieRHIV integrase, a brief overview from chemistry to therapeuticsJ Biol Chem200127626232132321611346660
   PubMed Web of Science ®Google Scholar
• LaFeminaRLSchneiderCLRobbinsHLRequirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cellsJ Virol19926612741474191433523
   PubMed Web of Science ®Google Scholar
• HazudaDBlauCUFelockPIsolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolitesAntivir Chem Chemother1999102637010335400
   PubMed Web of Science ®Google Scholar
• HazudaDJAnthonyNJGomezRPA naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integraseProc Natl Acad Sci U S A200410131112331123815277684
   PubMed Web of Science ®Google Scholar
• PaisGCZhangXMarchandCStructure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitorsJ Med Chem200245153184319412109903
   PubMed Web of Science ®Google Scholar
• EmbreyMWWaiJSFunkTWA series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cellsBioorg Med Chem Lett200515204550455416102965
   PubMed Web of Science ®Google Scholar
• EspesethASFelockPWolfeAHIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integraseProc Natl Acad Sci U S A20009721112441124911016953
   PubMed Web of Science ®Google Scholar
• HareSGuptaSSValkovEEngelmanACherepanovPRetroviral intasome assembly and inhibition of DNA strand transferNature2010464728623223620118915
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoERapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyJ Acquir Immune Defic Syndr200746212513317721395
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAPetryASSafety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsClin Pharmacol Ther200883229329917713476
   PubMed Web of Science ®Google Scholar
• WenningLAHanleyWDBrainardDMEffect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of ralteg ravirAntimicrob Agents Chemother20095372852285619433563
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAMistryGCAtazanavir modestly increases plasma levels of raltegravir in healthy subjectsClin Infect Dis200847113714018513146
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoESustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionJ Acquir Immune Defic Syndr200952335035619648823
   PubMed Web of Science ®Google Scholar
• LennoxJLDeJesusELazzarinASafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet2009374969279680619647866
   PubMed Web of Science ®Google Scholar
• MetznerKJAllersKRauchPHarrerTRapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patientsAIDS200721670371117413691
   PubMed Web of Science ®Google Scholar
• LennoxJLDejesusEBergerDSRaltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJ Acquir Immune Defic Syndr2010551394820404738
   PubMed Web of Science ®Google Scholar
• GrinsztejnBNguyenBYKatlamaCSafety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialLancet200736995691261126917434401
   PubMed Web of Science ®Google Scholar
• CooperDASteigbigelRTGatellJMSubgroup and resistance analyses of raltegravir for resistant HIV-1 infectionN Engl J Med2008359435536518650513
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDAKumarPNRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDATepplerHLong-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsClin Infect Dis201050460561220085491
   PubMed Web of Science ®Google Scholar
• MartínezELarrousseMLlibreJMSubstitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyAIDS201024111697170720467288
   PubMed Web of Science ®Google Scholar
• de CastroNBraunJCharreauISwitch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialClin Infect Dis20094981259126719757993
   PubMed Web of Science ®Google Scholar
• RoquebertBDamondFCollinGHIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitroJ Antimicrob Chemother200862591492018718922
   PubMed Web of Science ®Google Scholar
• EronJJYoungBCooperDASwitch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsLancet2010375971239640720074791
   PubMed Web of Science ®Google Scholar
• DamondFLarivenSRoquebertBVirological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patientsAIDS200822566566618317013
   PubMed Web of Science ®Google Scholar
• GarrettNXuLSmitEFernsBEl-GadiSAndersonJRaltegravir treatment response in an HIV-2 infected patient: a case reportAIDS20082291091109218520356
   PubMed Web of Science ®Google Scholar
• LeozMDepatureauxAVessièreAIntegrase polymorphism and HIV-1 group O diversityAIDS200822101239124318525277
   PubMed Web of Science ®Google Scholar
• BrizVGarridoCPovedaERaltegravir and etravirine are active against HIV type 1 group OAIDS Res Hum Retroviruses200925222522719239363
   PubMed Web of Science ®Google Scholar
• CharpentierCUnalGDepatureauxAIn vivo Virological Response in HIV-1 Group O-infected Patients to Different Antiretroviral Line RegimensInternational HIV and Hepatitis Virus Drug Resistance Workshop and Curative StrategiesDubrovnik, Croatia201068–12 Abstract 111
   Google Scholar
• YazdanpanahYFagardCDescampsDHigh rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialClin Infect Dis20094991441144919814627
   PubMed Web of Science ®Google Scholar
• MouscadetJFDelelisOMarcelinAGTchertanovLResistance to HIV-1 integrase inhibitors: a structural perspectiveDrug Resist Updat Epub201064
   Web of Science ®Google Scholar
• FransenSGuptaSDanovichRLoss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathwaysJ Virol20098322114401144619759152
   PubMed Web of Science ®Google Scholar
• SekiTKobayashiMWakasa-MorimotoCS/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. [Abstract 555]17th Conference on Retroviruses and Opportunistic InfectionsSan Francisco, CA, USA2010 Feb.
   Google Scholar
• Bar-MagenTSloanRDDonahueDAIdentification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitorJ Virol201084189210921620610719
   PubMed Web of Science ®Google Scholar
• FransenSKarmochkineMHuangWWeissLPetropoulosCJCharpentierCLongitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failureAntimicrob Agents Chemother200953104522452419667293
   PubMed Web of Science ®Google Scholar
• MaletIDelelisOSoulieCQuasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsJ Antimicrob Chemother200963479580419221102
   PubMed Web of Science ®Google Scholar
• CharpentierCKarmochkineMLaureillardDDrug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapyHIV Med20089976577018651855
   PubMed Web of Science ®Google Scholar
• GhosnJMazetAAAvettand-FenoelVRapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimenJ Antimicrob Chemother200964243343419457931
   PubMed Web of Science ®Google Scholar
• GallienSDelaugerreCHuZIntegrase inhibitor resistance mutations in treatment-experienced HIV-1-infected patients with low-level viremia receiving raltegravir-containing antiretroviral therapy: an ANRS 138-EASIER trial substudyInternational HIV and Hepatitis Virus Drug Resistance Workshop and Curative StrategiesDubrovnik, Croatia201068–12; Abstract 49.
   Google Scholar
• CharpentierCRoquebertBColinCResistance analyses in highly-experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen (ANRS 139 TRIO trial)AIDS Epub2010826
   Web of Science ®Google Scholar
• MillerMDDanovichRMKeYLongitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005, a phase II study in treatment-experienced patientsAntivir Ther200813Suppl 3A8
   Google Scholar
• QuerciaRDamEPerez-BercoffDClavelFSelective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypesJ Virol20098319102451024919605484
   PubMed Web of Science ®Google Scholar
• HatanoHLampirisHFransenSEvolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapyJ Acquir Immune Defic Syndr201054438939320300008
   PubMed Web of Science ®Google Scholar
• ReigadasSAniesGMasquelierBThe HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functionsPLoS One201054e1031120436677
   PubMed Web of Science ®Google Scholar
• CharpentierCLaureillardDPikettyCHigh frequency of integrase Q148R minority variants in HIV-infected patients naïve of integrase inhibitorsAIDS201024686787320160635
   PubMed Web of Science ®Google Scholar
• Ceccherini-SilbersteinFvan BaelenKArmeniaDSecondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitorsAntimicrob Agents Chemother20105493938394820479206
   PubMed Web of Science ®Google Scholar
• LiuJMillerMDanovichRDetection of low-frequency mutations associated with drug resistance to raltegravir before ART [Abstract 685]16th Conference on Retroviruses and Opportunistic InfectionsMontreal; Canada2009 Feb
   Google Scholar
• CabyFValinNMarcelinAGRaltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsScand J Infect Dis2010426/752753220222846
   PubMedGoogle Scholar
• AllavenaCMounouryORodallecARaltegravir in HIV-1 ARV-experienced patients: high efficacy and absence of emergence of resistance mutations in low-grade virologic failures. [Abstract PE7.9/15]12th European AIDS Conference/EACSKoln, GermanyNov 2009
   Google Scholar